Completed
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
NCT02565576
- Conditions
- Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Immune System Diseases, +11 more
- Locations
-
- Novartis Investigative Site Montreal, Quebec, Canada
- Novartis Investigative Site Québec, Quebec, Canada
- Novartis Investigative Site Aarhus, Denmark
- Novartis Investigative Site Copenhagen, Denmark